Search

Search Results

• PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse¹, Marta Mosca², David A Isenberg³, Joan T Merrill⁴, Thomas Dörner⁵, Michelle Petri⁶, Edward M Vital^7|8, Eric F Morand⁹, Teri Jimenez¹⁰, Stephen Brookes¹¹, Janine Gaiha-Rohrbach¹², Christophe Martin¹³, Annette Nelde¹⁴, Christian Stach¹⁵ | ¹Duke University - Division of Rheumatology and Immunology Durham, USA; ²University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; ³University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; ⁴Oklahoma Medical Research Foundation Oklahoma City, USA; ⁵Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; ⁶Johns Hopkins University School of Medicine Baltimore, USA; ⁷University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; ⁸Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; ⁹Monash University - Centre for Inflammatory Diseases Melbourne, Australia; ¹⁰UCB Raleigh, USA; ¹¹Biogen Maidenhead, United Kingdom; ¹²Biogen Cambridge, USA; ¹³UCB Slough, United Kingdom; ¹⁴Biogen Baar, Switzerland; ¹⁵UCB Monheim am Rhein, Germany

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2318

  144
• 

  From anatomy to therapy: the historical journey to cortisone

  Ernesto Damiani, Piero Marson, Francesco M. Galassi

  19-11-2025

  https://doi.org/10.4081/reumatismo.2025.1935

  3072

  Downloads: 850